Analyst Price Targets — QTTB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 24, 2026 8:47 am | Judah Frommer | Morgan Stanley | $34.00 | $15.97 | StreetInsider | Morgan Stanley Starts Q32 Bio Inc. (QTTB) at Overweight |
| July 28, 2026 10:00 am | Joseph Pantginis | H.C. Wainwright | $36.00 | $15.21 | StreetInsider | Q32 Bio Inc. (QTTB) PT Raised to $36 at H.C. Wainwright |
| July 13, 2026 1:37 pm | Derek Archila | Wells Fargo | $66.00 | $20.29 | TheFly | Q32 Bio upgraded to Overweight at Wells Fargo after alopecia areata study data |
| July 13, 2026 1:32 pm | — | Oppenheimer | $40.00 | $20.72 | StreetInsider | Q32 Bio Inc. (QTTB) PT Raised to $40 at OppenheimerMember Login |
| May 22, 2026 8:33 am | Joseph Catanzaro | Mizuho Securities | $14.00 | $5.50 | TheFly | Q32 Bio initiated with an Outperform at Mizuho |
| March 10, 2026 4:20 pm | Joseph Pantginis | H.C. Wainwright | $13.00 | $5.99 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key clinical data" |
| December 5, 2024 9:10 pm | Etzer Darout | BMO Capital | $64.00 | $23.69 | StreetInsider | BMO Capital Starts Q32 Bio Inc. (QTTB) at Outperform |
| October 16, 2024 6:22 am | Jay Olson | Oppenheimer | $80.00 | $48.47 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Q32 Bio Inc. (QTTB) |
| September 11, 2024 5:27 am | Derek Archila | Wells Fargo | $95.00 | $50.61 | StreetInsider | Wells Fargo Starts Q32 Bio Inc. (QTTB) at Overweight |
| May 21, 2024 6:22 am | Thomas Smith | Leerink Partners | $54.00 | $30.20 | TheFly | Q32 Bio initiated with an Outperform at Leerink |
Latest News for QTTB
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8,…
The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing -- -- Registration-directed program evaluating bempikibart in patients with…
The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTTB.
U.S. House Trading
No House trades found for QTTB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.